Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 2/20 | 0.49 |
| ▸ | PTGES | O14684 | 2/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.47 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4906143 | 0.91 | MAPT (0.49) | LMNANR3C1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4902984 | 0.91 | ALDH1A1 (0.50) | LMNANR3C1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4906440 | 0.90 | LMNA (0.61) | LMNANR3C1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4905563 | 0.90 | ALDH1A1 (0.44) | LMNANR3C1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4903818 | 0.89 | ESR1 (0.52) | LMNANR3C1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4908278 | 0.89 | ALDH1A1 (0.48) | LMNANR3C1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4903860 | 0.89 | HCRTR2 (0.51) | LMNANR3C1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4903963 | 0.89 | ALDH1A1 (0.43) | LMNANR3C1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4895683 | 0.88 | HDAC8 (0.50) | LMNAALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4906103 | 0.86 | LMNA (0.49) | LMNAALDH1A1MAPTSMN1; SMN2MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20060229363-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | HAMANAKA ERNEST S | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229363-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | PPARA, PPARG, PPARD | LMNA 317/4885NR3C1 179/4885ALDH1A1 2664/4885 |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PPARA, PPARG, PPARD | LMNA 319/4885NR3C1 169/4885ALDH1A1 2956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.